devic outflow impact perform view
signal chang investor approach
sector amid pullback select opportun emerg
devic sentiment broadli chang sinc late-august peak devic
trade lag broader healthcar pt pt
still outperform pt pt year devic sit
premium vs week ago clear healthcar continu lag devic
perform rel in-lin growth indic sinc late august
bullish consid prior out-performance pt late august
broader valu growth revers pt sinc peak small-cap devic
under-perform pronounc declin pt sinc peak
evid investor may re-evalu appropri multipl
single-product growth asset nuanc highlight previous
light polit climat investor chang way view devic
simpli dont think back improv growth polit
insul see devic fare favor vs healthcar head
remain solid follow construct manag commentari
healthcar confer see despit pullback expect remain
elev note hospit survey model impli bp
momentum acceler follow broader rebound
would modestli histor trend seen analysi gener
speak expect compani deliv estim model impli less
guidanc come
hillrom stock fulli reflect growth acceler ceo
john groetelaar pt under-perform new lrp like take
increment step forward organ growth vs core growth
provid lrp along bp margin expans
commit double-digit earn growth expect
guidanc core growth double-digit underli ep growth
ex-surg consum divestitur impli report basi
voalt recent refinanc could sourc upsid
bd manag confid growth despit bp
impli acceler organ outlook like fall
rang consist recent commentari ep growth outlook
less certain adjust bard deal model impli growth
fx worsen bd need invest given offset
return rel current stock price
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
lower ep growth consensu
insid
irhythm quarterli beat enough year given
reimburs overhang combin quarter
reimburs clariti could one-two punch stock need
expect upsid sale ama note octob
wont definit societi support impli greater work valu
zio may lessen likelihood draconian cut
see continu improv commerci organ
street sale estim still look conserv given
q/q trend impli declin upsid remain construct
omnia launch catalyst see stock rebound
pdn data nan
nuvas expect upsid organ growth estim
puls traction remain underappreci puls placement
like drive mn revenu pt growth uptak
drive upsid us spine estim pt momentum
decel would lowest growth rate sinc insid
time contrarian
 litig impact js defens environ
share outperform materi opioid see talc risk
like price despit daubert talc hear later month
potenti revers missouri rule clear catalyst path
legal resolut cloud legal clariti pharma acceler
defens characterist could shift sentiment near-term
dont see materi pharma upsid
abiom continu lag growth manag sound ok
guidanc low end confer given
expect sit evid stabil could drive relief
notwithstand dilig support manag narr
rp tavr ail channel commerci disrupt structur
growth issu take longer one quarter fix without definit
catalyst convinc quarter clear
elev expect littl easier ew
zimmer biomet sell day dynam recent manag
commentari led investor expect upper end cc growth
howev zimmer biomet remain recoveri stori deliv
cc growth set forth last quarter acceler rosa placement
enough drive stock higher
share pull back larg cap growth peer
quarter still see potenti upsid street model
pt momentum deceler easier neotract comp
sustain reason investor concern see
durabl organ growth achiev fx concern ep
see increment headwind vs prior guidanc remain
edward edward two name
outperform year post-peak sell-off
admit creat high bar dilig suggest low-risk inflect
occur see tavr growth enough sustain
momentum model pt momentum deceler
view conserv given stabil impli beat
last quarter inflect like sustain
medic devic outperform bp
under-perform devic pt devic outperform provid
servic pharma ls tool
within coverag ortho cardio show strongest
perform suppli equip under-perform sector
med-tech sector
med-tech capit
ntm price-to-earnings rel
ntm price-to-earnings rel
exhibit cardio ntm price-to-earnings rel
exhibit ortho ntm price-to-earnings rel
exhibit suppli ntm price-to-earnings rel
exhibit organ growth med-tech segment
exhibit year stack organ growth med-tech segment
exhibit organ growth capit
exhibit yr stack organ growth capit
exhibit ms med-tech coverag base case return rel
current stock price
return rel current stock price
million except ep
comfort organ growth comfort
organ growth estim midpoint
guidanc line organ
growth impli momentum stabil stabil devic
bp deceler epd bp deceler nutrit
driven weak china pediatr bp
acceler dx aler improv growth possibl
see modest upsid overal organ growth
estim upper half rang intra-quart fx
headwind leav us comfort midpoint
ep rang line worsen fx make less
like see ep guidanc rais unlik prior year
manag gener rais opioid litig
unlik big focu call remain depend
purdu process see deep dive
libr key focu call diabet model
ad patient last quarter instal base surpass
patient comfort estim
note increment diabet sale bp
corpor growth libr focal point manag
remain confid icgm admittedli direct guidanc
libr timelin approv year confus
look forward addit updat call
mitraclip acceler ahead ncd coapt landmark trial mitraclip
fundament chang treatment paradigm secondari function mitral
regurgit fmr patient said near-term challeng
promin tvt/tct includ identifi appropri patient cohort establish
protocol team appropri patient manag drive referr us
mitraclip growth improv market
acceler remain comfort us growth estim
impli stabil mitra-fr still somewhat impact referr ex us
continu expect ncd next key catalyst adopt
estim remain risk-adjust mitraclip pascal see
potenti upsid driven ncd anniversari mitra-fr disrupt pascal
launch ex us see
million except ep
street estim achiev unlik
clear sale estim line street
achiev impli bp q/q declin vs q/q
growth prior two year still remain unclear
drove acut slowdown impella growth begin two
quarter ago manag commentari suggest driven
transient issu commerci disrupt rp warn
letter structur shift matur market
increas focu tavr volum pci light low risk
approv see tavr volum driven low-risk
continu improv remaind calendar year
continu pressur impella volum
causal factor declin impella growth
guidanc appropri remain comfort
y/i growth line closer low end
guidanc rang backhalf look risk adjust
absorb increment slowdown busi pt
momentum deceler
focu rebuild commerci infrastructur manag
remain focus rebuild commerci infrastructur focu broad base
increment sale rep clinic support well middl manag senior
chang expect increas invest commerci infrastructur help
stabil growth time expect rebuild happen multipl
quarter expect addit updat call
million except ep
model model revenu in-lin
consensu reflect cc growth
expect surgic revenu impli cc growth
pt momentum deceler given slightli higher
consum comp lower q/q growth equip saw
addit dilig suggest reimburs
adjust cataract procedur may potenti
impact equip capit purchas
interest commentari earn call vision
model revenu repres cc growth
rel momentum stabil in-lin manag
guidanc sequenti om improv throughout
model bp improv bp
improv bottom line look
ep consensu
eye panoptix updat commentari around
cadenc product rollout initi physician feedback
recent panoptix dilig point posit
import detail manag provid broader
cataract procedur trend toward higher
end share dynam within at-iol segment
end commentari johnson johnson call prior
alcon may drive level sentiment quarter
competit commentari around softer us refract
remain earli day setup improv alcon lag large-cap
coverag sinc report despit deliv solid top-lin quarter
announc us launch panoptix august modestli
ahead expect broader growth unwind one driver
weak potenti concern around ep visibl may contribut see
note thesi intact ep explain believ setup improv share
spin-out level product-driven top-line acceler margin
improv closer view believ detail earli
panoptix commerci traction ep dynam interest expens tax would
well receiv
million except ep
expect in-lin quarter expect revenu
in-lin consensu impli cc growth
organ growth number base
chronic revenu come neom
impli momentum deceler follow strong
given difficult comp pain manag
revenu impli momentum acceler see
continu msd declin on-q busi model
bp q/q improv growth given lower
guidanc see on-q remain pain point predic
persist on-q headwind commentari trajectori
improv manag expect on-q return
growth focu though expect
updat guidanc quarter also look detail
summit integr transact yet close
within pain manag avano remain confid
sustain coolief growth model in-lin
expect coolief contribut
oper margin improv street may high
expect oper margin continu improv throughout driven
lower invest spend larg relat coolief cost save
continu build model oper margin bp
see om impli bp y/i improv sens
om expans look similar therefor model bp
expans vs street increment om
worth ep explain differ ep
estim street view consensu number like
come
see near-term acquisit remain key focu
manag follow ip divestitur posit case avano would
involv execut deal corpak-lik profil compani
capac deploy near-term continu expect deal would remain rel
small potenti larger deal cost transform plan
million except ep
oab approv greater catalyst follow axon r-snm
devic approv fi septemb see focu
shift oab approv see immin month
greater focu rel number extent
axon receiv approv prior earn releas see
commentari around scale us commerci effort
paramount look updat earli experi
axon us salesforc sale rep hire
complet year high-volum implant physician
throughout countri engag trend around fi could
provid earli indic oab adopt
conserv model flat revenu model
sale entir europ canada in-lin
consensu estim impli flat q/q revenu view
approach prudent given like season fact remain earli
day howev could see upsid number base increas ex-u market share
axon estim reach market share england canada
also remain focus expans netherland
germani near-term addit axon recent announc plan expans
franc norway could becom impact ex-u revenu
expect compani provid guidanc quarter given yet
make first us shipment expect manag provid
around trajectori sale growth next month import
gm improv off-set opex model gross margin improv back
half given ramp volum model reflect bp expans
follow anoth bp compani begin us shipment off-set
oper expens tick higher throughout year consist manag
commentari opex ramp full-scal us launch model reflect
opex modestli
million except ep
model line guidanc model organ
growth ex cyclo consist guidanc
line consensu comfort baxter abil
deliv guidanc base continu improv
deliveri model pt momentum
acceler discuss ii softer comp us
nutrit combin shift tender order ex us iii
continu contribut recent pharma launch model
ep line consensu
model pt deliveri acceler deliveri
recoveri key tenet baxter upgrad januari
segment guidanc primari debat baxter stock
year recent healthcar confer see
manag indic increas confid compani
abil deliv highlight primarili predic
upgrad compani exist custom base
origin imb materi share gain indic upgrad
track accord plan compani also gain
share believ achiev increasingli de-risk
model pt deliveri acceler impli organ growth
segment revenu
margin guidanc remain play model oper margin impli
bp expans drive margin toward midpoint
guidanc expans context bp headwind
brevi cyclo fx impli bp underli improv
remain comfort addit cyclo brevi data august point
like beat across two inject vs mse primarili attribut
cyclo beat partial off-set modest miss brevi run-rat basi also
note new competit come northstar rx cyclo launch juli
gener revenu end august base im data
tailwind outpac headwind expect baxter continu benefit
variou tailwind aggreg head includ anniversari
hd contract exit cyclo brevi headwind moder increment
myxredlin expand esrd reimburs new molecul launch
tie scinopharm partnership off-set tailwind
note manag visibl bp headwind includ
floseal benefit dexm benefit anniversari deliveri
return
million except ep
comfort organ remain comfort
organ growth estim line
morgan stanley healthcar confer manag
reiter confid bp acceler requir
deliv growth line impli growth
low end guidanc manag also reiter
confid margin step-up despit greater optic
ep line
outlook expect organ growth guidanc
consist manag commentari greater
confid bottom half bard deal
model addit given multipl earn disconnect
incom ceo transit conserv initi guidanc
prudent remain comfort low end rang
path top half rang driven mix improv
dcb growth btk see expect updat
fda process btk call expect btk
includ guid doubl digit report earn may
risk fx swing factor high teen underli earn
off-set bp gore royalti bp tarrif fx
could bp headwind bp fx
bd could deliv ep growth bp impli
report ep lower ep vs
y/i growth comfort given
intermedi term outlook previous unclear manag could deliv
top-line growth/margin expans driven doubl digit earn outlook
morgan stanley healthcar confer manag reiter comfort
sustain organ growth doubl digit growth beyond bard deal
model expect manag deliv similar messag call
million except ep
comfort lower half guidanc model
organ growth line low end
organ guidanc rang estim impli bp
momentum acceler seem like easi hurdl
light mix result first half sens manag
acut awar need deliv quarter
model reflect bp momentum acceler cardiolog
driven sentinel turn organ lotu launch
watchman bp acceler rm bp
acceler medsurg part due nxthera turn organ
note concern data ischemia trial
present aha novemb may limit upsid even solid
quarter given boston de complex pci
focu structur heart manag reiter structur
heart guidanc tct encourag
guidanc give limit insight impact acur near-
term scope inferior data note acur drop
trend y/i growth flattish growth impli
headwind absorb watchman/lotu model
structur heart sale comfort lower half
btg visibl clear btg growth slow mid teen low doubl digit
prolong acquisit period discuss dynam btg playbook
manag remain confid growth slowdown weight commerci
disrupt due deal commentari suggest competit pressur
notic dvt/pe ex eko bundl ex us distribut key driver
deal boston alreadi start see benefit cross-sel pi
alreadi begun distribut btg product certain ex us geographi btg
revenu mix nearli us ex-zytiga possibl btg ex us mix grow
line broader boston pi underappreci investor
look forward updat call pleas see deep dive btg
million except ep
guidanc revenu impli y/i
growth model high-end rang year
sale come larg in-lin consensu
impli y/i growth contribut
total fy revenu model y/i growth us impli
pt momentum deceler view conserv
ex-u model y/i growth impli momentum stabil
pleas see note address ex-u concern follow
recent healthcar confer view
misconstru expect estim prove conserv
given continu robust new patient add recent
track record revenu beat compani deliv
beat vs estim past consecut quarter
deliv momentum stabil minimum
time frame momentum stabil quarter impli
top-lin beat expect would provid rais
least line beat expect limit gm improv
quarter model bp expans consist
manag commentari improv
signific compani like exit year
product scale
libr icgm commentari focu despit fail receiv approv date
dilig suggest abbott broader data present ada
continu expect libr receiv approv icgm design year
given length time pass libr signific focu abbott
earn call prior commentari like drive sentiment
extent quarter said would expect minim impact new
patient add given continu expand penetr
lrp continu look conserv although maintain lrp
guidanc sinc decemb analyst day sens remain
target revenu appear conserv number impli
compound-annual-growth-rate compani posit deliv growth
continu pursu premium price strategi given premium offer
although manag recent comment plan price
compar level libr look greater disclosur price strategi
